©2018 by Mana Therapeutics.

email contact: crcruz@manatherapeutics.com

FOUNDERS

Catherine Bollard M.D., MBChB

Catherine Bollard M.D., MBChB is the director of the Center for Cancer and Immunology Research at the Children’s Research Institute, a member of the Division of the Blood and Marrow Transplantation, and the Director of the Program for Cell Enhancement and Technologies for Immunotherapy. In this role, she leads clinical and research efforts to fight cancer and other inflammatory diseases by strengthening a child’s immune system. As the immediate past President of the International Society of Cellular Therapy, she is a distinguished hematologist and immunotherapist, working to develop cell and gene therapies for patients with cancer and underlying immune deficiencies.

Patrick Hanley, Ph.D.

Patrick Hanley, Ph.D. is an assistant research professor of pediatrics in the Center for Cancer and Immunology research at the Children’s Research Institute, a member of the Division of Blood and Marrow Transplantation, and a member of the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System. He is the director of the Good Manufacturing Practices (GMP) facility where novel cell therapies developed in the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) are translated and manufactured for early stage clinical trials.

C. Russell Y. Cruz, M.D., Ph.D.

C. Russell Y. Cruz, M.D., Ph.D. is the Director of the Translational Research Laboratory of the Program for Cell Enhancement and Technologies for Immunotherapy, and is an Assistant Professor, Tenure Track at George Washington University/Children’s National Medical Center. Dr. Cruz aims to learn from previous success targeting viral infections in transplant recipients and apply this knowledge towards development of novel therapies against malignancy. Dr. Cruz’s research program focuses on developing cells that can jump start endogenous immunity against brain tumors and solid tumors.

Marc Cohen, Executive Chairman

Marc A. Cohen is Co-founder and Executive Chairman of C4 Therapeutics.  Marc is also the Co-founder and Chief Executive Officer of Bublup, Inc; Neuro Tennis, Inc.; and COBRO Ventures, Inc.; as well as the Co-founder and Chairman of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc., two biotech companies spun out of Dana-Farber Cancer Institute and Harvard University. In addition, Marc was the Co-founder, Chief Executive Officer, and Chairman of OPNET Technologies, Inc (Nasdaq: OPNT), a world leader in network and application performance management. OPNET was sold to Riverbed Technology (Nasdaq: RVBD) in December 2012.

 

Marc received a Bachelor of Science in engineering from Harvard University and a Master of Science in electrical engineering from Stanford University. Marc is a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients.  Marc enjoys tennis, yoga, and photography, and still hopes to figure out golf one day.